Kezar Life Sciences
4000 Shoreline Ct
Suite 300
South San Francisco
94080
United States
Tel: 650-822-5600
Website: http://www.kezarlifesciences.com/
Email: contact@kezarbio.com
108 articles about Kezar Life Sciences
-
Kezar Life Sciences to Participate in Two Upcoming Investor Conferences in September 2021
9/2/2021
Kezar Life Sciences, Inc., a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, announced members of the executive team will participate in the following upcoming virtual investor conferences.
-
Kezar Life Sciences Announces Completion of Enrollment of Its Phase 2 PRESIDIO Clinical Trial of KZR-616 in Polymyositis and Dermatomyositis
8/23/2021
Kezar Life Sciences, Inc., a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, announced that PRESIDIO, its Phase 2 clinical trial to evaluate the safety and efficacy of KZR-616 for the treatment of polymyositis and dermatomyositis completed the target enrollment of 24 subjects.
-
Kezar Life Sciences Reports Second Quarter 2021 Financial Results and Provides Business Updates
8/12/2021
Kezar Life Sciences, Inc., a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, announced its second quarter 2021 financial results and corporate highlights.
-
Kezar Life Sciences to Participate in the William Blair Biotech Focus Conference 2021
7/8/2021
Kezar Life Sciences, Inc. today announced its Co-founder and Chief Scientific Officer, Christopher Kirk, will participate in the “Novel Targets for Autoimmune Diseases” panel discussion at William Blair's Biotech Focus Conference on Thursday, July 15, 2021, at 11:00 a.m. ET.
-
Kezar Life Sciences Announces Formation of Clinical Advisory Committee
6/8/2021
Kezar Life Sciences, Inc., a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, announced the formation of its Clinical Advisory Committee.
-
Kezar Presents Results of the Completed MISSION Phase 1b Study of KZR-616 at EULAR 2021
6/2/2021
KZR-616 demonstrates improvement across all exploratory efficacy measures and is observed to be well-tolerated up to 75 mg subcutaneously once weekly for 13 weeks.
-
Kezar Life Sciences to Participate in the Jefferies Virtual Healthcare Conference
5/27/2021
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced its Chief Executive Officer, John Fowler, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 2:00 p.m. ET.
-
Kezar Life Sciences to Host Virtual MISSION Phase 1b Data Update Call at EULAR 2021 on June 2, 2021
5/26/2021
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that it will host a MISSION Phase 1b data update call for investors and analysts during the European Congress of Rheumatology (EULAR 2021) on Wednesday, June 2, 2021 at 4:30 p.m. ET.
-
Kezar Life Sciences Reports First Quarter Financial Results and Provides Business Updates
5/12/2021
KZR-616 clinical development in three severe autoimmune diseases is advancing with several data readouts expected in 2021 and 2022
-
Kezar Life Sciences Recognized as 2021 Bay Area Best Places to Work
5/10/2021
Kezar Life Sciences, Inc., a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, has been recognized as a winner of the 2021 Bay Area Best Places to Work, an awards program presented by the San Francisco Business Times and the Silicon Valley Business Journal.
-
Kezar Life Sciences Presents Preclinical Data with IND Candidate KZR-261 at American Association for Cancer Research (AACR) 2021 Virtual Annual Meeting
4/10/2021
Kezar Life Sciences, Inc., a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, presented preclinical data on the company’s novel protein secretion program during two poster sessions at the American Association for Cancer Research 2021 Virtual Annual Meeting.
-
Kezar Life Sciences to Participate at Cowen 41st Annual Virtual Health Care Conference
2/25/2021
Kezar Life Sciences, Inc., a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, announced its Chief Executive Officer, John Fowler, will participate in the “Autoimmune/Complement” panel discussion at the Cowen 41st Annual Virtual Health Care Conference on Wednesday, March 3, 2021 at 11:40am EST.
-
Kezar Life Sciences to Present at BIO CEO & Investor Digital Conference
2/10/2021
Kezar Life Sciences, Inc. (Nasdaq:KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced its Chief Executive Officer, John Fowler, will present a corporate overview at the BIO CEO & Investor Digital Conference
-
Kezar Life Sciences to Present During Upcoming Virtual Investor Conferences
11/12/2020
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced members of the executive team will present during upcoming virtual investor conferences.
-
Kezar Highlights Broad Therapeutic Potential of KZR-616 During ACR Convergence 2020
11/5/2020
Kezar Life Sciences, Inc. (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today highlighted the broad therapeutic potential of KZR-616, a first-in-class immunopr
-
Kezar Life Sciences Reports Third-Quarter 2020 Financial Results and Provides Business Updates
11/5/2020
FDA grants two Orphan Drug Designations to KZR-616 for the treatment of Dermatomyositis (DM) and Polymyositis (PM)
-
Kezar Life Sciences Announces Orphan Drug Designations for KZR-616 for the Treatment of Polymyositis and Dermatomyositis
10/23/2020
Kezar Life Sciences, Inc., a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, announced that the U.S. Food and Drug Administration has granted Orphan Drug Designations for KZR-616 for the treatment of polymyositis and dermatomyositis.
-
Kezar Life Sciences to Present at Four Upcoming Virtual Medical and Scientific Conferences
10/15/2020
Cytokines 2020 and SITC presentations to showcase Sec61 inhibition as a novel mechanism for blocking expression of therapeutically relevant targets such as cytokines and immune checkpoints
-
Kezar Life Sciences to Present at The Myositis Association International Annual Patient Conference and the Pan-American Congress of Rheumatology
9/10/2020
-Engaging with patient community and presenting overview of PRESIDIO study at The Myositis Association’s (TMA) International Annual Patient Conference -Scientific poster presentation on MISSION Phase 1b study data at 22 nd Pan-American Congress of Rheumatology 2020 (PANLAR 2020)
-
Kezar Life Sciences to Participate in Upcoming Virtual Investor Conferences
9/3/2020
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced members of the executive team will present during upcoming virtual investor conferences. The details of the presentations are as follows: Wells Fargo 2020 Virtual Biotech Conference Fireside Chat: